Search
daclizumab (Zinbryta)
Withdrawn from worldwide market March 2018 due to reports of meningoencephalitis in Europe [5]
Indications:
- organ transplantation
- pancreatic islet cell transplantation
- cardiac transplantation
- lung transplantation
- renal graft rejection [3]
- multiple sclerosis [4]
- inadequate response to >= 2 MS drugs
Adverse effects:
- hepatotoxicity, increased serum ALT
- hypersensitivity reactions (anaphylaxis or angioedema)
- increased risk of infections
- symptoms of depression &/or suicidal ideation
- most common
- pharyngitis, nasopharyngitis, upper respiratory tract infection
- rash, dermatitis, eczema
- influenza,
- lymphdenopathy
- increased serum ALT
- depression
- meningoencephalitis [5]
Mechanism of action:
- monoclonal antibody against interleukin-2 receptor
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
General
pharmaceutical monoclonal antibody
recombinant protein; chimer
immunosuppressive agent
References
- Journal Watch 20(17):133, 2000
- Medical Knowledge Self Assessment Program (MKSAP) 16,
American College of Physicians, Philadelphia 2012
- Deprecated Reference
- FDA News Release. May 27, 2016
FDA approves Zinbryta to treat multiple sclerosis.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm
- George J
MS Drug Daclizumab Pulled from Worldwide Market
Inflammatory encephalitis, meningoencephalitis reported in Europe .
MedPage Today, March 2, 2018
https://www.medpagetoday.com/neurology/multiplesclerosis/71501
- FDA Drug Safety & Availability. March 14, 2018
FDA working with manufacturers to withdraw Zinbryta from the
market in the United States.
https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm